Hepatitis C virus in the new era:Perspectives in epidemiology,prevention,diagnostics and predictors of response to therapy

• Published in: World journal of gastroenterology : WJG Vol. 20; no. 29; pp. 9633 - 9652
• Main Authors: Ansaldi, Filippo, Orsi, Andrea, Sticchi, Laura, Bruzzone, Bianca, Icardi, Giancarlo
• Format: Journal Article
• Language: English
• Published: United States Baishideng Publishing Group Inc 07.08.2014
• Subjects: Antiviral Agents - therapeutic use; Developing Countries; Disease Progression; Drug Resistance, Viral; Endemic Diseases - prevention & control; epidemiology; Genotype; Hepacivirus - drug effects; Hepacivirus - genetics; Hepacivirus - pathogenicity; Hepatitis; Hepatitis C - diagnosis; Hepatitis C - drug therapy; Hepatitis C - epidemiology; Hepatitis C - genetics; Hepatitis C - prevention & control; Host-Pathogen Interactions; Humans; Pharmacogenetics; Predictive Value of Tests; Risk Factors; Topic Highlight; Treatment Outcome; virus; Hepatitis C virus diagnosis; Hepatitis C virus vaccine; Predictors of response to hepatitis C virus therapy; Hepatitis C virus epidemiology; Direct-acting antivirals
• ISSN: 1007-9327; 2219-2840
• DOI: 10.3748/wjg.v20.i29.9633

Despite the great successes achieved in the fields of virology and diagnostics,several difficulties affect improvements in hepatitis C virus(HCV)infection control and eradication in the new era.New HCV infections still occur,especially in some of the poorest regions of the world,where HCV is endemic and long-term sequelae have a growing economic and health burden.An HCV vaccine is still no available,despite years of researches and discoveries about the natural history of infection and host-virus interactions:several HCV vaccine candidates have been developed in the last years,targeting different HCV antigens or using alternative delivery systems,but viral variability and adaption ability constitute major challenges for vaccine development.Many new antiviral drugs for HCV therapy are in preclinical or early clinical development,but different limitations affect treatment validity.Treatment predictors are important tools,as they provide some guidance for the management of therapy in patients with chronic HCV infection:in particular,the role of host genomics in HCV infection outcomes in the new era of direct-acting antivirals may evolve for new therapeutic targets,representing a chance for modulated and personalized treatment management,when also very potent therapies will be available.In the present review we discuss the most recent data about HCV epidemiology,the new perspectives for the prevention of HCV infection and the most recent evidence regarding HCV diagnosis,therapy and predictors of response to it.